Patents by Inventor Jan Poolman

Jan Poolman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine
    Patent number: 8926985
    Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: January 6, 2015
    Assignee: GlaxoSmithKline Biologicals S A
    Inventors: Carine Capiau, Marguerite Deschamps, Pierre Michel Desmons, Craig Antonyjoseph Laferriere, Jan Poolman, Jean-Paul Prieels
  • Immunogenic composition
    Patent number: 8883163
    Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 11, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • VACCINE COMPOSITION
    Publication number: 20140294935
    Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.
    Type: Application
    Filed: May 12, 2014
    Publication date: October 2, 2014
    Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, George Thiry, Joelle Thonnard, Pierre Voet
  • TREATMENT OF STREPTOCOCCAL INFECTIONS
    Publication number: 20140205634
    Abstract: Methods of treating a Streptococcus pneumoniae infection are described herein.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 24, 2014
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe DENOEL, Philippe Vincent HERMAND, Steve LABBE, Jan POOLMAN, Stephane RIOUX
  • Immunogenic composition
    Patent number: 8703148
    Abstract: The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine group on PNAG to form a PNAG conjugate. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising PNAG and Type 5 and/or 8 capsular polysaccharides are also described.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: April 22, 2014
    Assignee: GlaxoSmithKline Biologicals S.A
    Inventors: Ralph Leon Biemans, Philippe Denoel, Pierre Duvivier, Tomas Maira-Litran, Jan Poolman
  • VACCINE AGAINST STREPTOCOCCUS PNEUMONIAE
    Publication number: 20140099339
    Abstract: The present invention relates to a combination of 2 or more S pneumoniae proteins, their manufacture and use in medicine as a vaccine. Such combinations are particularly useful for the protection of infants and elderly against streptococcal infection.
    Type: Application
    Filed: December 10, 2013
    Publication date: April 10, 2014
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe Hermand, Craig A. J. Laferriere, Yves Lobet, Jan Poolman
  • Serum bactericidal assay for specific antisera
    Patent number: 8679770
    Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.
    Type: Grant
    Filed: September 5, 2005
    Date of Patent: March 25, 2014
    Assignee: Glaxo Smith Kline Biologicals S.A.
    Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan Poolman, Vincent Weynants
  • VACCINE AGAINST STREPTOCOCCUS PNEUMONIAE
    Publication number: 20140072622
    Abstract: The present invention relates to improved immunogenic compositions and vaccines, methods for making them and their use in medicine. In particular the invention relates to immunogenic compositions of unconjugated Streptococcus pneumoniae proteins selected from: pneumolysin and member(s) of the Polyhistidine Triad family (e.g. PhtD), which comprise adjuvants comprising QS21 and monophosphoryl lipid A (MPL), and are presented in the form of a liposome.
    Type: Application
    Filed: May 15, 2012
    Publication date: March 13, 2014
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe Denoel, Jan Poolman, Vincent Verlant, Hugues Wallemacq
  • FUSION PROTEINS AND COMBINATION VACCINES COMPRISING HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A
    Publication number: 20140056934
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Application
    Filed: April 12, 2012
    Publication date: February 27, 2014
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • Pertussis antigens and use thereof in vaccination
    Patent number: 8574596
    Abstract: The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. The invention further provides immunogenic compositions comprising a plurality of antigens selected from at least two different categories of antigen, having different functions within Bordetella. Examples of such categories of antigen are autotransporter proteins, iron acquisition proteins, lipoproteins, adhesins and toxins/invasins.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: November 5, 2013
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Cindy Castado, Philippe Denoel, Fabrice Godfroid, Jan Poolman
  • VACCINE COMPOSITION
    Publication number: 20130266609
    Abstract: The present invention relates to DTP-based combination vaccine formulations, and concomitantly administered combination vaccine kits. Methods of administration of these vaccines and kits are also provided.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 10, 2013
    Inventors: DOMINIQUE BOUTRIAU, Carine Capiau, Pierre Michel Desmons, Dominique Lemoine, Jan Poolman
  • VACCINE
    Publication number: 20130251745
    Abstract: The present invention relates to the field of vaccines and in particular to combination vaccines and co-administration schedules. The present inventors disclose that overuse of CRM in paediatric vaccines can result in bystander immune interference to certain antigens and provide solutions to this problem.
    Type: Application
    Filed: May 17, 2013
    Publication date: September 26, 2013
    Applicant: Glaxosmithkline Biologicals S.A.
    Inventor: JAN POOLMAN
  • IMMUNOGENIC COMPOSITION
    Publication number: 20130171188
    Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.
    Type: Application
    Filed: February 27, 2013
    Publication date: July 4, 2013
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Ralph Leon BIEMANS, Dominique BOUTRIAU, Carine CAPIAU, Philippe DENOEL, Pierre DUVIVIER, Jan POOLMAN
  • Immunogenic composition
    Patent number: 8431136
    Abstract: An immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates is provided, wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of all the at least two further bacterial saccharide conjugates.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: April 30, 2013
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • Immunogenic composition
    Patent number: 8398983
    Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ug.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: March 19, 2013
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • IMMUNOGENIC COMPOSITION
    Publication number: 20130045231
    Abstract: Compositions for the treatment or prevention of Neisserial infection and methods for their use and manufacture are provided herein.
    Type: Application
    Filed: March 10, 2011
    Publication date: February 21, 2013
    Inventors: Jan Poolman, Cindy Castado, Vincent Weynants, Nathalie Isabelle Devos
  • IMMUNOGENIC COMPOSITION
    Publication number: 20130011429
    Abstract: Immunogenic compositions and methods of their use, as well as processes for their production are provided herein.
    Type: Application
    Filed: March 10, 2011
    Publication date: January 10, 2013
    Inventors: Jan Poolman, Cindy Castado, Vincent Weynants, Nathalie Isabelle Devos
  • VACCINE COMPOSITION
    Publication number: 20130004530
    Abstract: Neisserial immunogenic compositions and vaccines, their manufacture and methods for the use of such compositions in medicine are provided herein.
    Type: Application
    Filed: March 10, 2011
    Publication date: January 3, 2013
    Inventors: Jan Poolman, Cindy Castado, Vincent Weynants, Nathalie Isabelle Devos
  • VACCINE
    Publication number: 20130004510
    Abstract: Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.
    Type: Application
    Filed: March 11, 2011
    Publication date: January 3, 2013
    Inventors: Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Nathalie Isabelle Devos, Vincent Weynants
  • TREATMENT OF STREPTOCOCCAL INFECTIONS
    Publication number: 20120328659
    Abstract: Immunogenic compositions and methods of treating a Streptococcus pneumoniae infection are described herein.
    Type: Application
    Filed: March 8, 2011
    Publication date: December 27, 2012
    Inventors: Philippe Denoel, Philippe Vincent Hermand, Steve Labbe, Jan Poolman, Stephane Rioux